Melanoma: a model for testing new agents in combination therapies.
Treatment for both early and advanced melanoma has changed little since the introduction of interferon and IL-2 in the early 1990s. Recent data from trials testing targeted agents or immune modulators suggest the promise of new strategies to treat patients with advanced melanoma. These include a new generation of B-RAF inhibitors with greater selectivity for the mutant protein, c-Kit inhibitors, anti-angiogenesis agents, the immune modulators anti-CTLA4, anti-PD-1, and anti-CD40, and adoptive cellular therapies. The high success rate of mutant B-RAF and c-Kit inhibitors relies on the selection of patients with corresponding mutations. However, although response rates with small molecule inhibitors are high, most are not durable. Moreover, for a large subset of patients, reliable predictive biomarkers especially for immunologic modulators have not yet been identified. Progress may also depend on identifying additional molecular targets, which in turn depends upon a better understanding of the mechanisms leading to response or resistance. More challenging but equally important will be understanding how to optimize the treatment of individual patients using these active agents sequentially or in combination with each other, with other experimental treatment, or with traditional anticancer modalities such as chemotherapy, radiation, or surgery. Compared to the standard approach of developing new single agents for licensing in advanced disease, the identification and validation of patient specific and multi-modality treatments will require increased involvement by several stakeholders in designing trials aimed at identifying, even in early stages of drug development, the most effective way to use molecularly guided approaches to treat tumors as they evolve over time.
Ascierto
Paolo A
PA
Unit of Medical Oncology and Innovative Therapy, National Tumor Institute, Naples, Italy. paolo.ascierto@gmail.com
Streicher
Howard Z
HZ
Sznol
Mario
M
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D008954:Models, Biological; D015398:Signal Transduction / Q000187:drug effects
D000970:Antineoplastic Agents
N Engl J Med. 2009 Jul 9;361(2):189-91
19553640
Front Biosci. 2006 Jan 01;11:733-42
16146765
Mol Cancer Ther. 2009 Oct;8(10):2872-81
19825805
J Clin Oncol. 2006 Nov 1;24(31):5034-42
17075123
Cell. 2009 May 29;137(5):835-48
19490893
Med Pediatr Oncol. 1982;10(3):251-8
7045615
N Engl J Med. 2005 Nov 17;353(20):2135-47
16291983
Cancer. 2009 Jan 1;115(1):119-27
19090009
J Clin Virol. 2010 Apr;47(4):335-9
20138803
Science. 2009 Mar 27;323(5922):1747-50
19251594
Curr Pharm Des. 2005;11(14):1805-43
15892677
J Clin Oncol. 1997 Jul;15(7):2579-88
9215828
Clin Cancer Res. 2009 Dec 1;15(23):7277-90
19934293
Ann Oncol. 2006 Apr;17(4):571-7
16469753
Cancer Res. 2008 Jun 15;68(12):4853-61
18559533
J Clin Oncol. 2007 Jun 1;25(16):e20-1
17538155
J Clin Oncol. 2008 May 1;26(13):2178-85
18445842
J Clin Oncol. 2002 Mar 15;20(6):1600-7
11896110
Hematol Oncol Clin North Am. 2009 Jun;23(3):529-45, ix
19464601
J Clin Oncol. 2008 Jul 20;26(21):3653-4; author reply 3654-5
18640948
N Engl J Med. 2006 Dec 7;355(23):2408-17
17151364
Cancer Immunol Immunother. 2009 Nov;58(11):1749-59
19551381
Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17777-82
17968018
J Clin Oncol. 1996 Jul;14(7):2083-90
8683240
J Clin Oncol. 2007 May 20;25(15):1955-6
17513801
J Clin Oncol. 1999 Mar;17(3):968-75
10071291
N Engl J Med. 2009 Jul 9;361(2):123-34
19553641
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5232-7
17875749
Oncologist. 2008;13 Suppl 4:16-25
19001147
Nat Genet. 2009 Oct;41(10):1127-32
19718025
Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22299-304
20007781
J Clin Invest. 2008 Nov;118(11):3660-70
18924608
Cancer Cell. 2005 Oct;8(4):287-97
16226704
J Clin Oncol. 2007 May 1;25(13):1760-4
17470866
J Clin Oncol. 2009 Jul 1;27(19):3073-6
19451415
Cancer Lett. 2009 Oct 8;283(2):125-34
19217204
J Clin Oncol. 2009 Jun 10;27(17):2823-30
19349552
Blood. 2009 Jul 16;114(3):535-46
19451549
J Transl Med. 2009 Oct 14;7:86
19828018
Cancer Res. 2008 Aug 15;68(16):6708-17
18701495
Hematol Oncol Clin North Am. 2009 Jun;23(3):547-64, ix-x
19464602
Nature. 2002 Jun 27;417(6892):949-54
12068308
J Natl Cancer Inst. 2007 Oct 3;99(19):1455-61
17895472
Clin Cancer Res. 2008 Jan 15;14(2):342-6
18223206
J Clin Oncol. 2005 Sep 20;23(27):6747-55
16170182
J Clin Oncol. 2000 Jan;18(1):158-66
10623706
Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12480-4
18711136
J Clin Oncol. 2006 Oct 10;24(29):4738-45
16966688
J Clin Oncol. 2010 Jan 1;28(1):92-8
19933921
J Clin Oncol. 2009 Nov 20;27(33):5650-9
19858389
J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3
17895470
Nature. 2010 Mar 18;464(7287):427-30
20179705
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
19934295
Oncologist. 2008;13 Suppl 4:10-5
19001146
Curr Opin Immunol. 2009 Apr;21(2):233-40
19304471
Nature. 2010 Mar 18;464(7287):431-5
20130576
Curr Pharm Des. 2004;10(16):1907-14
15180527
J Clin Oncol. 2008 Dec 10;26(35):5748-54
19001327
Science. 2009 Dec 18;326(5960):1619
20019269
J Clin Oncol. 1999 Sep;17(9):2745-51
10561349
Pigment Cell Melanoma Res. 2009 Jun;22(3):246-7
19397758
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900
17392427
Nat Rev Cancer. 2008 Sep;8(9):705-13
19143055
Ann Oncol. 2007 Oct;18(10):1691-7
17709802
N Engl J Med. 1992 Aug 20;327(8):516-23
1635566
Expert Rev Anticancer Ther. 2009 May;9(5):567-81
19445574
Clin Cancer Res. 2009 Dec 1;15(23):7116-8
19934296
J Clin Oncol. 2002 Apr 15;20(8):2045-52
11956264
Clin Cancer Res. 2009 Jan 1;15(1):324-9
19118061
Br J Cancer. 2000 Mar;82(6):1158-62
10735499
J Clin Oncol. 1998 May;16(5):1743-51
9586887
Cancer Metastasis Rev. 2010 Mar;29(1):151-70
20112054
Mol Pharmacol. 2009 May;75(5):1231-9
19246337